Shared Inflammatory Pathway Linking HS and Metabolic Syndrome
A common cytokine axis drives both diseases together.
- TNF-α / IL-17: Key cytokines (shared HS-MetS drivers)
- ~40%: MetS in HS cohorts (reported prevalence estimate)
- Common: CRP elevation (systemic inflammation marker)
- Bidirectional: Onset pattern (each may worsen the other)
Cytokine overlap between HS and metabolic disease
Placeholder: TNF-α and IL-17 link follicular inflammation to insulin resistance.
Placeholder: shared inflammation supports routine metabolic screening in HS.
Waist Circumference and Obesity as an HS Risk Amplifier
Central obesity worsens follicular occlusion and disease severity.
- ~50-70%: Obesity prevalence in HS (higher than general population)
- >88 cm: Waist cutoff (women) (ATP III criterion)
- >102 cm: Waist cutoff (men) (ATP III criterion)
- Improves HS: Weight loss effect (reduces flare frequency)
Mechanical and hormonal effects of central adiposity
Placeholder: adipose tissue adds mechanical friction and adipokine-driven inflammation.
Placeholder: waist measurement should be routine at every HS visit.
Insulin Resistance and Type 2 Diabetes Risk in HS
Chronic inflammation drives measurable insulin resistance in HS.
- ~2x: T2D risk increase (versus matched controls)
- >100 mg/dL: Fasting glucose cutoff (MetS criterion)
- Frequent: HOMA-IR elevation (even without diabetes diagnosis)
- Annual: Screening interval (suggested fasting glucose check)
Why insulin resistance tracks with HS severity
Placeholder: worsening Hurley stage correlates with rising insulin resistance markers.
Placeholder: consider HbA1c testing alongside dermatologic HS evaluation.
Hypertension and Dyslipidemia Screening in HS Patients
Blood pressure and lipid panels are frequently overlooked in HS.
- ≥130/85: BP cutoff (MetS criterion threshold)
- <40/50 mg/dL: Low HDL cutoff (men/women threshold)
- ≥150 mg/dL: Triglyceride cutoff (MetS criterion)
- Elevated: Cardiovascular risk (in moderate-severe HS)
Integrating cardiometabolic panels into HS follow-up
Placeholder: routine BP and lipid checks catch silent cardiometabolic risk.
Placeholder: pair dermatology visits with periodic cardiometabolic screening.
Combined Comorbidity Management for HS and Metabolic Syndrome
Coordinated multidisciplinary care improves both conditions together.
- Derm + Endo + PCP: Recommended team (multidisciplinary model)
- First-line: Lifestyle intervention (diet, activity, weight management)
- Anti-TNF/IL-17: Biologic therapy overlap (may benefit both conditions)
- Every 3-6 mo: Follow-up cadence (suggested joint review)
Building an integrated HS-metabolic care pathway
Placeholder: shared care pathways reduce fragmented, delayed comorbidity treatment.
Placeholder: screen every HS patient for metabolic syndrome at diagnosis.